Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3518)	4/21/2001 9:11:56 PM
From: aknahow	Respond to of 52153

Thanks for the reply. Xoma certainly has been more volatile than ICOS. The charts reflect the FDA delayed BLA filing for Neuprex in use with Meningococcemia. Looked at a chart of ICOS compared to XOMA and found it difficult to come to any conclusion. quote.yahoo.com Still remember the day I thought I was too smart to buy more ICOS thru a rights offering around three dollars a share because I knew the prospectus clearly said the shares would have a book value of about $1.60 after the offering. What did Gates know that I didn't? Well live and learn. <g> Am interested in which drug you think has the best chance for approval and if you think both will make it thru, which do you think will do better in the market, Amevive or Xanelim?